Posterior Tibial Nerve Stimulation With versus Without Mirabegron: A Randomized Controlled Trial

Area of Science:

• Urology
• Pharmacology
• Clinical Trials

Background:

• Refractory urgency urinary incontinence (UUI) poses a significant challenge in women's health.
• Current treatments like antimuscarinic medications may have intolerable side effects or limited efficacy.
• Posterior tibial nerve stimulation (PTNS) is an established treatment for UUI.

Purpose of the Study:

• To evaluate the efficacy of combination therapy (PTNS plus mirabegron) versus monotherapy (PTNS plus placebo) for refractory UUI.
• To determine if mirabegron enhances the effectiveness of PTNS in reducing UUI episodes.
• To assess the impact on other overactive bladder symptoms and quality of life.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 54 women with refractory UUI.
• Participants received either PTNS with mirabegron or PTNS with placebo for 12 weeks.
• Outcomes measured included changes in UUI episodes, urinary frequency, and validated symptom questionnaires.

Main Results:

• The combination therapy group showed a significantly greater reduction in mean UUI episodes compared to the placebo group (9.4 vs. 5.3 episodes, p=0.007).
• Significant improvements were also observed in urinary frequency and symptom-related quality of life scores in the combination arm.
• No significant demographic differences were noted between the treatment groups at baseline.

Conclusions:

• The addition of mirabegron to PTNS significantly improves objective and subjective outcomes for women with refractory UUI and overactive bladder symptoms.
• Combination therapy represents a more effective treatment strategy than PTNS monotherapy for this patient population.
• This finding supports the use of mirabegron as an adjunct to PTNS for managing challenging UUI cases.